Compare Repligen Corporation Common Stock (RGEN) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard Real Estate Index Fund ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Vanguard Real Estate Index Fund ETF trades at $90.36 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 6.4× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| RGEN | VNQ | |
|---|---|---|
Market Cap | $11.14B | $70.80B |
Volume | 1,259,263 | 3,568,223 |
Sector | Health | — |
52-Week High | $194.57 | $100.95 |
52-Week Low | $102.87 | $87.00 |
Typical Hold Time | 0 Days | 113 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VNQ, the Vanguard Real Estate ETF, trades at $91.14, down 0.24% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Recent news highlights pressure from rising Treasury yields and Fed rate hikes, contributing to a nearly 10% decline over the past month. The ETF's dividend yield is now competitive with T-bills, but sector headwinds persist due to interest rate sensitivity.
Outlook remains cautious amid interest rate uncertainty, with potential long-term value for contrarian investors. Risks include further rate hikes eroding income appeal, while opportunities lie in historically attractive entry points for well-capitalized REITs. Investors should weigh yield sustainability against macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
